Tamara Maher, DO
Adult Medicine · Los Alamitos, CANPI 1598750473
Payments from drug & device makers
Across 635 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$2K
- AstraZeneca$1K
- GSK$982
- Johnson & Johnson$851
- Bausch Health US, LLC$681
- plus $4K from 26 others
What the payments were for
- Food & beverage$12,100100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 125 | $2,001 |
| Amgen(2 entities) | 69 | $1,798 |
| AstraZeneca | 60 | $1,422 |
| GSK | 47 | $982 |
| Johnson & Johnson | 54 | $851 |
| Bausch Health US, LLC | 49 | $681 |
| AbbVie(2 entities) | 31 | $627 |
| Pfizer | 43 | $516 |
| Amarin Pharma, Inc. | 27 | $444 |
| Abbott | 8 | $333 |
| Novartis | 17 | $325 |
| Phathom Pharmaceuticals, Inc. | 14 | $303 |
| Exact Sciences | 14 | $264 |
| Edwards Lifesciences | 5 | $194 |
| Merck | 9 | $175 |
| Lilly USA, LLC | 8 | $146 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $135 |
| Bayer | 6 | $117 |
| Kowa Pharmaceuticals America, Inc. | 6 | $99 |
| Boehringer Ingelheim | 4 | $93 |
| Alkermes, Inc. | 4 | $88 |
| Scilex Pharmaceuticals Inc. | 4 | $78 |
| Sanofi-aventis U.S. LLC | 4 | $75 |
| Astellas Pharma US Inc | 3 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Arbor Pharmaceuticals, Inc. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Dexcom, Inc. | 2 | $39 |
| Mannkind Corporation | 1 | $27 |
| Esperion Therapeutics, Inc. | 1 | $26 |
| Evofem Biosciences, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,107 in reported general payments places this provider in the 90th percentile of 221 adult medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 71 | $113,989 |
| JardianceEmpagliflozin | 67 | $69,455 |
| OzempicSemaglutide | 62 | $64,737 |
| EliquisApixaban | 63 | $63,293 |
| FarxigaDapagliflozin Propanediol | 56 | $61,929 |
| MounjaroTirzepatide | 40 | $53,313 |
| VascepaIcosapent Ethyl | 36 | $26,533 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $22,510 |
| Xigduo XrDapaglifloz Propaned/Metformin | 21 | $20,100 |
| KerendiaFinerenone | 16 | $15,634 |
| EdarbiAzilsartan Medoxomil | 25 | $13,360 |
| JanuviaSitagliptin Phosphate | 21 | $12,133 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $11,402 |
| Diclofenac Sodium | 20 | $11,241 |
| DapagliflozinDapagliflozin Propanediol | 12 | $9,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $2,001 | $178,727133 claims |
| Boehringer IngelheimJardiance | $93 | $69,45567 claims |
| PfizerEliquis | $516 | $63,29363 claims |
| AstraZenecaFarxiga | $1,422 | $61,92956 claims |
| Lilly USA, LLCMounjaro | $146 | $53,31340 claims |
| GSKTrelegy Ellipta | $982 | $22,51026 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $56 | $21,25045 claims |
| BayerKerendia | $117 | $15,63416 claims |
| MerckJanuvia | $175 | $12,13321 claims |
| AbbVieSynthroid | $627 | $3,40240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 221 adult medicine providers in California.
Other adult medicine in Los Alamitos
- Gary BooneSan Diego$4.9M
- Salil NadkarniWest Hollywood$3.3M
- Robert FerreraSacramento$2.6M
- Ramin FarsadEncinitas$2.2M
- Susan HutchinsonLaguna Hills$1M
- Natalia GuzmanLos Angeles$583K
- Yasuko KidokoroSan Diego$267K
- Richard FauselRancho Mirage$30K
- Benedicto EstoestaValley Springs$22K
- Antoine DipsiaW. Sacramento$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.